rentradВестник рентгенологии и радиологииJournal of radiology and nuclear medicine0042-46762619-0478Limited Liability Company "LUCHEVAYA DIAGNOSTIKA", Russian Association of Radiologists10.20862/0042-4676-2014-0-2-66-72rentrad-24Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS OF LITERATUREМАГНИТНО-РЕЗОНАНСНАЯ ТОМОГРАФИЯ В СТАДИРОВАНИИ ЛИМФОМMAGNETIC RESONANCE IMAGING IN THE STAGING OF MALIGNANT LYMPHOMASМихайловА. И.MikhaylovA. I.

аспирант

ул. Баррикадная, 2/1, Москва, 123995

Postgraduate

ul. Barrikadnaya, 2/1, Moscow, 123995

azatmihailov@gmail.comТюринИ. Е.TyurinI. E.

д. м. н., профессор, заведующий кафедрой лучевой диагностики, лучевой терапии и медицинской физики

ул. Баррикадная, 2/1, Москва, 123995

MD, PhD, DSc, Professor, Head of Department of Radiodiagnosis, Radiotherapy and Medical Physics

ul. Barrikadnaya, 2/1, Moscow, 123995

ПановВ. О.PanovV. O.

к. м. н., доцент кафедры лучевой диагностики, лучевой терапии и медицинской физики 

ул. Баррикадная, 2/1, Москва, 123995

MD, PhD, Associate Professor of Department of Radiodiagnosis, Radiotherapy and Medical Physics

ul. Barrikadnaya, 2/1, Moscow, 123995

ГБОУ ДПО «Российская медицинская академия последипломного образования» Министерства здравоохранения РФРоссияRussian Medical Academy of Postgraduate Education, Ministry of Health of the RFRussian Federation201427022016026067Copyright © Михайлов А.И., Тюрин И.Е., Панов В.О., 20162016Михайлов А.И., Тюрин И.Е., Панов В.О.Mikhaylov A.I., Tyurin I.E., Panov V.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.russianradiology.ru/jour/article/view/24

Компьютерная томография (КТ), позитронная эмиссионная томография (ПЭТ) с 18F-фтордезоксиглюкозой (ФДГ) и совмещенная одномоментная ПЭТ/КТ наиболее часто используются для первичного стадирования и оценки эффективности терапии при злокачественных лимфомах. Различные технологии магнитно-резонансной томографии, такие как МРТ всего тела и получение диффузионно-взвешенных изображений, могут стать альтернативой ПЭТ/КТ, свободной от ионизирующего излучения. Диффузионно-взвешенные изображения, отличающиеся высокой чувствительностью в отношении обнаружения патологических очагов и возможностью проведения количественной оценки диффузии молекул воды, могут помочь в изучении злокачественной лимфомы. В данной статье рассмотрены преимущества новых методов МРТ для начального стадирования и оценки эффективности терапии при злокачественных лимфомах. 

Computed tomography, 18FDG-PET and the hybrid FDGPET/CT are the most commonly used diagnostic tools for the initial staging and treatment response assessment of malignant lymphomas. MRI techniques such as whole-body MRI and diffusionweighted imaging may become good radiation-free alternatives to FDG-PET/CT. Diffusion-weighted imaging is characterized by high sensitivity for the detection of lesions and allows quantitative assessment of diffusion that may aid in the evaluation of malignant lymphomas. This article will review the value of these emerging MRI techniques for the staging and response assessment of malignant lymphoma.

злокачественные лимфомыстадированиемагнитно-резонансная томография (МРТ)МРТ всего телапозитронная эмиссионная томографиякомпьютерная томографияmalignant lymphomastagingmagnetic resonance imaging (MRI)whole-body MRIpositron emission tomographycomputed tomographyReferencesJaffe E. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. ASH Education Book. 2009; 2009 (1): 523–31.Jaffe E. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. ASH Education Book. 2009; 2009 (1): 523–31.Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 2007; 57: 43–66.Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 2007; 57: 43–66.Zinzani P.L. Lymphoma: diagnosis, staging, natural history, and treatment strategies. Semin. Oncol. 2005; 32 (1 Suppl. 1): S4–S10.Zinzani P.L. Lymphoma: diagnosis, staging, natural history, and treatment strategies. Semin. Oncol. 2005; 32 (1 Suppl. 1): S4–S10.Castellino R.A, Podoloff D.A. Diagnostic radiology and nuclear medicine. In: Mauch P.M., Armitage J.O., Diehl V., Hoppe R.T., Weiss L.M. (eds) Hodgkin’s dis￾ease. Philadelphia: Lippincott Williams & Wilkins. 1999: 241–62.Castellino R.A, Podoloff D.A. Diagnostic radiology and nuclear medicine. In: Mauch P.M., Armitage J.O., Diehl V., Hoppe R.T., Weiss L.M. (eds) Hodgkin’s dis￾ease. Philadelphia: Lippincott Williams & Wilkins. 1999: 241–62.Armitage J. Lymphomas. Eds by G. Canellos, T.A. Lister, J.L. Sklar. 1st ed. Philadelphia; London: W.B. Saunders Company; 1998: 439, 449.Armitage J. Lymphomas. Eds by G. Canellos, T.A. Lister, J.L. Sklar. 1st ed. Philadelphia; London: W.B. Saunders Company; 1998: 439, 449.Mendenhall N.P. Diagnostic procedures and guidelines for the evaluation and follow-up of Hodgkin’s disease. Semin. Radiat. Oncol. 1996; 6: 131–45.Mendenhall N.P. Diagnostic procedures and guidelines for the evaluation and follow-up of Hodgkin’s disease. Semin. Radiat. Oncol. 1996; 6: 131–45.Connors J.M. State-of-the-art therapeutics: Hodgkin’s lymphoma. J. Clin. Oncol. 2005; 23: 6400–8.Connors J.M. State-of-the-art therapeutics: Hodgkin’s lymphoma. J. Clin. Oncol. 2005; 23: 6400–8.Alberta Provincial Hematology Tumour Team syntesis. Lymphoma. Clinical practice guideline LYHE-002. (2013). Avaiable at: http://www. albertahealthservices.ca/hp/if-hp-cancer-guide-lyne002-lymphoma.pdfAlberta Provincial Hematology Tumour Team syntesis. Lymphoma. Clinical practice guideline LYHE-002. (2013). Avaiable at: http://www. albertahealthservices.ca/hp/if-hp-cancer-guide-lyne002-lymphoma.pdfGuidelines on Diagnosis and Treatment of Malignant Lymphomas, Lymphoma forum of Ireland. (2010). Avaiable at: http://haematologyireland.org/meetings/documents/Lymphoma-GuidelinesonDiagnosisandTreatmentofMalignantLymphomas.pdfGuidelines on Diagnosis and Treatment of Malignant Lymphomas, Lymphoma forum of Ireland. (2010). Avaiable at: http://haematologyireland.org/meetings/documents/Lymphoma-GuidelinesonDiagnosisandTreatmentofMalignantLymphomas.pdfKwee T.C., Kwee R.M., Nievelstein R.A. Imaging in staging of malignant lymphoma: a systematic review. Blood. 2008; 111: 504–16.Kwee T.C., Kwee R.M., Nievelstein R.A. Imaging in staging of malignant lymphoma: a systematic review. Blood. 2008; 111: 504–16.Nogami M. et al. Diagnostic performance of CT, PET, side-by-side, and fused image interpretations for restaging of non-Hodgkin lymphoma. Ann. Nucl. Med. 2007; 21: 189–96.Nogami M. et al. Diagnostic performance of CT, PET, side-by-side, and fused image interpretations for restaging of non-Hodgkin lymphoma. Ann. Nucl. Med. 2007; 21: 189–96.Schoder H., Larson S.M., Yeung H.W. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J. Nucl. Med. 2004; 45 (1): 72S–81S.Schoder H., Larson S.M., Yeung H.W. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J. Nucl. Med. 2004; 45 (1): 72S–81S.Vermoolen M.A., Kersten M.J., Fijnheer R. Magnetic resonance imaging of malignant lymphoma. Expert Reviews Hematology. 2011; 4 (2): 161–71.Vermoolen M.A., Kersten M.J., Fijnheer R. Magnetic resonance imaging of malignant lymphoma. Expert Reviews Hematology. 2011; 4 (2): 161–71.Cheson D., Pfistner B., Juweid M.E. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 2007; 25 (5): 579–86.Cheson D., Pfistner B., Juweid M.E. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 2007; 25 (5): 579–86.Moskowitz C.H., Schröder H., Teruya-Feldstein J. et al. Risk-adapted dosedense immunochemotherapy determinated by interim FDG￾PET in advanced-stage diffuse large B-cell lymphoma. J. Clin. Oncol. 2010; 28: 1896–903.Moskowitz C.H., Schröder H., Teruya-Feldstein J. et al. Risk-adapted dosedense immunochemotherapy determinated by interim FDG￾PET in advanced-stage diffuse large B-cell lymphoma. J. Clin. Oncol. 2010; 28: 1896–903.Vinicombe S., Reznek R.H. Computerized tomography in the staging of Hodgkin’s disease and non￾Hodgkin’s lymphoma. Eur. J. Nucl. Med. 2003; 30 (1): 42–55.Vinicombe S., Reznek R.H. Computerized tomography in the staging of Hodgkin’s disease and non￾Hodgkin’s lymphoma. Eur. J. Nucl. Med. 2003; 30 (1): 42–55.La Fougè re C., Hundt W., Bröckel N. et al. Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur. J. Nucl. Med. Mol. Imaging. 2006; 33 (12): 1417–25.La Fougè re C., Hundt W., Bröckel N. et al. Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur. J. Nucl. Med. Mol. Imaging. 2006; 33 (12): 1417–25.Kumral A., Olgun N., Uysal K.M., Corapcioglu F., Oren H., Sarialioglu F. Assessment of peripheral lymphadenopathies: experience at a pediatric hematology-oncology department in Turkey. Pediatr. Hematol. Oncol. 2002; 19 (4): 211–8.Kumral A., Olgun N., Uysal K.M., Corapcioglu F., Oren H., Sarialioglu F. Assessment of peripheral lymphadenopathies: experience at a pediatric hematology-oncology department in Turkey. Pediatr. Hematol. Oncol. 2002; 19 (4): 211–8.Adams H.J.A., Kwee T.C., Vermoolen M.A. et al. Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. Eur. Radiol. 2013; 23: 2271–8.Adams H.J.A., Kwee T.C., Vermoolen M.A. et al. Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. Eur. Radiol. 2013; 23: 2271–8.Brepoels L., Stroobants S. PET scanning and prognosis in Hodgkin’s lymphoma. Curr. Opin. Oncol. 2008; 20 (5): 509–16.Brepoels L., Stroobants S. PET scanning and prognosis in Hodgkin’s lymphoma. Curr. Opin. Oncol. 2008; 20 (5): 509–16.Delbeke D., Stroobants S., de Kerviler E., Gisselbrecht C., Meignan M., Conti P.S. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist. 2009; 14 (2): 30–40.Delbeke D., Stroobants S., de Kerviler E., Gisselbrecht C., Meignan M., Conti P.S. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist. 2009; 14 (2): 30–40.Isasi C.R., Lu P., Blaufox M.D. A metaanalysis of 18F-FDG positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005; 104: 1066–74.Isasi C.R., Lu P., Blaufox M.D. A metaanalysis of 18F-FDG positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005; 104: 1066–74.Kabickova E., Sumerauer D., Cumlivska E. et al. Comparison of 18FFDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease. Eur. J. Nucl. Med. Mol. Imaging. 2006; 33: 1025–31.Kabickova E., Sumerauer D., Cumlivska E. et al. Comparison of 18FFDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease. Eur. J. Nucl. Med. Mol. Imaging. 2006; 33: 1025–31.Furth C., Denecke T., Steffen I. et al. Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease. J. Pediatr. Hematol. Oncol. 2006; 28: 501–12.Furth C., Denecke T., Steffen I. et al. Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease. J. Pediatr. Hematol. Oncol. 2006; 28: 501–12.Hutchings M., Loft A., Hansen M. et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica. 2006; 91; 482–9.Hutchings M., Loft A., Hansen M. et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica. 2006; 91; 482–9.Mikhaeel N.G., Hutchings M., Fields P.A. et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade nonHodgkin lymphoma. Ann. Oncol. 2005; 16: 1514–23.Mikhaeel N.G., Hutchings M., Fields P.A. et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade nonHodgkin lymphoma. Ann. Oncol. 2005; 16: 1514–23.Gallamini A., Rigacci L., Merli F. et al. Predictive value of positron emission tomography performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin disease. Haematologica. 2006; 91: 475–81.Gallamini A., Rigacci L., Merli F. et al. Predictive value of positron emission tomography performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin disease. Haematologica. 2006; 91: 475–81.Elstrom R., Guan L., Baker G. et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003; 101: 3875–6.Elstrom R., Guan L., Baker G. et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003; 101: 3875–6.Itti E., Lin C., Dupuis J. et al. Prognostic value of interim 18FFDG PET in patients with diffuse large B cell lymphoma:SUV-based assessment at four cycles of chemotherapy. J. Nucl. Med. 2009; 50: 527–33.Itti E., Lin C., Dupuis J. et al. Prognostic value of interim 18FFDG PET in patients with diffuse large B cell lymphoma:SUV-based assessment at four cycles of chemotherapy. J. Nucl. Med. 2009; 50: 527–33.Blodgett T.M., Meltzer C.C., Townsend D.W. PET/CT: form and function. Radiology. 2007; 242: 360–85.Blodgett T.M., Meltzer C.C., Townsend D.W. PET/CT: form and function. Radiology. 2007; 242: 360–85.Pelosi E., Pregno P., Penna D. et al. Role of whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol. Med. 2008; 113: 578–90.Pelosi E., Pregno P., Penna D. et al. Role of whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol. Med. 2008; 113: 578–90.Gossmann A., Eich H.T., Engert A. et al. CT and MR imaging in Hodgkin’s disease – present and future. Eur. J. Haematol. 2005; 75 (66): S83–S89.Gossmann A., Eich H.T., Engert A. et al. CT and MR imaging in Hodgkin’s disease – present and future. Eur. J. Haematol. 2005; 75 (66): S83–S89.Lister T.A., Crowther D., Sutcliffe S.B. et al. Report of committee converted to discuss the evaluation and staging of patients with Hodgkin’s disease: the Сotswold meeting. J. Clin. Oncol. 1989; 7: 1630–6.Lister T.A., Crowther D., Sutcliffe S.B. et al. Report of committee converted to discuss the evaluation and staging of patients with Hodgkin’s disease: the Сotswold meeting. J. Clin. Oncol. 1989; 7: 1630–6.Carbone P.P., Kaplan H.S., Musshoff K. et al. Report of the committee on Hodgkin’s disease staging. Cancer. Res. 1971; 26: 1860–1.Carbone P.P., Kaplan H.S., Musshoff K. et al. Report of the committee on Hodgkin’s disease staging. Cancer. Res. 1971; 26: 1860–1.Kwee T.C., Kwee R.M., Verdonck L.F., Bierings M.B., Nievelstein R.A. Magnetic resonance imaging for the detection of bone marrow involvement in malignant lymphoma. Br. J. Hematol. 2008; 111: 60–8.Kwee T.C., Kwee R.M., Verdonck L.F., Bierings M.B., Nievelstein R.A. Magnetic resonance imaging for the detection of bone marrow involvement in malignant lymphoma. Br. J. Hematol. 2008; 111: 60–8.Basu S., Torigian D., Alavi A. Evolving concept of imaging bone marrow metastasis in the twenty-first century: critical role of FDG-PET. Eur. J. Nucl. Med. Mol. Imaging. 2008; 35 (3): 465–71.Basu S., Torigian D., Alavi A. Evolving concept of imaging bone marrow metastasis in the twenty-first century: critical role of FDG-PET. Eur. J. Nucl. Med. Mol. Imaging. 2008; 35 (3): 465–71.Schmidt G.P., Wintersperger B., Graser A., Baur-Melnyk A., Reiser M.F., Schoenberg S.O. High resolution wholebody magnetic resonance imaging applications at 1.5 and 3 Tesla: a comparative study. Invest. Radiol. 2007; 42: 449–59.Schmidt G.P., Wintersperger B., Graser A., Baur-Melnyk A., Reiser M.F., Schoenberg S.O. High resolution wholebody magnetic resonance imaging applications at 1.5 and 3 Tesla: a comparative study. Invest. Radiol. 2007; 42: 449–59.Schick F. Whole-body MRI at high field: technical limits and clinical potential. Eur. Radiol. 2005; 15: 946–59.Schick F. Whole-body MRI at high field: technical limits and clinical potential. Eur. Radiol. 2005; 15: 946–59.Koh D.M., Collins D.J. Diffusion weighted MRI in the body: applications and challenges in oncology. Am. J. Roentgenol. 2007. 188: 1622–35.Koh D.M., Collins D.J. Diffusion weighted MRI in the body: applications and challenges in oncology. Am. J. Roentgenol. 2007. 188: 1622–35.Kwee T.C., Ludwig I., Uiterwaal C.S. et al. ADC measurements in the evaluation of lymph nodes in patients with non-Hodgkin lymphoma: feasibility study. MAGMA. 2011. 24 (1): 1–8.Kwee T.C., Ludwig I., Uiterwaal C.S. et al. ADC measurements in the evaluation of lymph nodes in patients with non-Hodgkin lymphoma: feasibility study. MAGMA. 2011. 24 (1): 1–8.Kwee T.C., Sandip Basu, Drew A. et al. Evolving importance of diffusion-weighted magnetic resonance imaging in lymphoma. PET Clinics. 2012; 7 (1): 1–138.Kwee T.C., Sandip Basu, Drew A. et al. Evolving importance of diffusion-weighted magnetic resonance imaging in lymphoma. PET Clinics. 2012; 7 (1): 1–138.Kwee T.C., Takahara T., Ochiai R., Nievelstein R.A., Luijten P.R. Diffusion weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur. Radiol. 2008; 18 (9): 1937–52.Kwee T.C., Takahara T., Ochiai R., Nievelstein R.A., Luijten P.R. Diffusion weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur. Radiol. 2008; 18 (9): 1937–52.Kwee T.C., van Ufford H.M., Beek F.J. et al. Whole-body MRI, including diffusion weighted imaging, for the initial staging of malignant lymphoma, comparison to computed tomography. Invest. Radiol. 2009; 44: 683–90.Kwee T.C., van Ufford H.M., Beek F.J. et al. Whole-body MRI, including diffusion weighted imaging, for the initial staging of malignant lymphoma, comparison to computed tomography. Invest. Radiol. 2009; 44: 683–90.Van Ufford H.M.E., Kwee T.C., Beek F.J. et al. Whole body MRI, including diffusion-weighted imaging, compared to 18F-FDG-PETCT in newly diagnosed lymphoma: initial results. Am. J. Roentgenol. 2011; 196 (3): 662–9.Van Ufford H.M.E., Kwee T.C., Beek F.J. et al. Whole body MRI, including diffusion-weighted imaging, compared to 18F-FDG-PETCT in newly diagnosed lymphoma: initial results. Am. J. Roentgenol. 2011; 196 (3): 662–9.Tilly H., Dreyling M., Group E.G.W. Diffuse large B-cell non-Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010; 21 (5): v172–v174.Tilly H., Dreyling M., Group E.G.W. Diffuse large B-cell non-Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010; 21 (5): v172–v174.Inaoka T., Takahashi K., Mineta M., et al. Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology. 2007; 243: 869–76.Inaoka T., Takahashi K., Mineta M., et al. Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology. 2007; 243: 869–76.Buchbender С., Heusner Т., Lauenstein T.C. et al. Oncologic PET/MRI, Part 1: Tumors of the Brain, Head and Neck, Chest, Abdomen, and Pelvis. J. Nuclear Med. 2012; 53 (6): 928–38.Buchbender С., Heusner Т., Lauenstein T.C. et al. Oncologic PET/MRI, Part 1: Tumors of the Brain, Head and Neck, Chest, Abdomen, and Pelvis. J. Nuclear Med. 2012; 53 (6): 928–38.Buchbender С., Heusner Т., Lauenstein T.C. et al. Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma. J. Nuclear Med. 2012; 53 (8): 1244–52.Buchbender С., Heusner Т., Lauenstein T.C. et al. Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma. J. Nuclear Med. 2012; 53 (8): 1244–52.

The authors declare that there are no conflicts of interest present.